238 related articles for article (PubMed ID: 34260816)
1. Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: Insights from the Caravaggio study.
Giustozzi M; Connors JM; Ruperez Blanco AB; Szmit S; Falvo N; Cohen AT; Huisman M; Bauersachs R; Dentali F; Becattini C; Agnelli G
J Thromb Haemost; 2021 Nov; 19(11):2751-2759. PubMed ID: 34260816
[TBL] [Abstract][Full Text] [Related]
2. Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial.
Becattini C; Bauersachs R; Maraziti G; Bertoletti L; Cohen A; Connors JM; Manfellotto D; Sanchez A; Brenner B; Agnelli G
Haematologica; 2022 Jul; 107(7):1567-1576. PubMed ID: 34382385
[TBL] [Abstract][Full Text] [Related]
3. Recurrent venous thromboembolism and major bleeding in patients with localised, locally advanced or metastatic cancer: an analysis of the Caravaggio study.
Verso M; Agnelli G; Munoz A; Connors JM; Sanchez O; Huisman M; Brenner B; Gussoni G; Cohen AT; Becattini C
Eur J Cancer; 2022 Apr; 165():136-145. PubMed ID: 35235870
[TBL] [Abstract][Full Text] [Related]
4. Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism.
Verso M; Munoz A; Bauersachs R; Huisman MV; Mandalà M; Vescovo G; Becattini C; Agnelli G
Eur J Cancer; 2021 May; 148():371-381. PubMed ID: 33780665
[TBL] [Abstract][Full Text] [Related]
5. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.
Agnelli G; Becattini C; Meyer G; Muñoz A; Huisman MV; Connors JM; Cohen A; Bauersachs R; Brenner B; Torbicki A; Sueiro MR; Lambert C; Gussoni G; Campanini M; Fontanella A; Vescovo G; Verso M;
N Engl J Med; 2020 Apr; 382(17):1599-1607. PubMed ID: 32223112
[TBL] [Abstract][Full Text] [Related]
6. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial.
McBane RD; Wysokinski WE; Le-Rademacher JG; Zemla T; Ashrani A; Tafur A; Perepu U; Anderson D; Gundabolu K; Kuzma C; Perez Botero J; Leon Ferre RA; Henkin S; Lenz CJ; Houghton DE; Vishnu P; Loprinzi CL
J Thromb Haemost; 2020 Feb; 18(2):411-421. PubMed ID: 31630479
[TBL] [Abstract][Full Text] [Related]
7. Clinical implications of incidental venous thromboembolism in cancer patients.
Mulder FI; Di Nisio M; Ay C; Carrier M; Bosch FTM; Segers A; Kraaijpoel N; Grosso MA; Zhang G; Verhamme P; Wang TF; Weitz JI; Middeldorp S; Raskob G; Beenen LFM; Büller HR; van Es N
Eur Respir J; 2020 Feb; 55(2):. PubMed ID: 31727694
[TBL] [Abstract][Full Text] [Related]
8. Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE Trial.
McBane Ii R; Loprinzi CL; Ashrani A; Perez-Botero J; Leon Ferre RA; Henkin S; Lenz CJ; Le-Rademacher JG; Wysokinski WE
Thromb Haemost; 2017 Oct; 117(10):1952-1961. PubMed ID: 28837207
[TBL] [Abstract][Full Text] [Related]
9. Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study.
Francis CW; Kessler CM; Goldhaber SZ; Kovacs MJ; Monreal M; Huisman MV; Bergqvist D; Turpie AG; Ortel TL; Spyropoulos AC; Pabinger I; Kakkar AK
J Thromb Haemost; 2015 Jun; 13(6):1028-35. PubMed ID: 25827941
[TBL] [Abstract][Full Text] [Related]
10. Apixaban and Dalteparin for the Treatment of Venous Thromboembolism in Patients with Different Sites of Cancer.
Agnelli G; Muñoz A; Franco L; Mahé I; Brenner B; Connors JM; Gussoni G; Hamulyak EN; Lambert C; Suero MR; Bauersachs R; Torbicki A; Becattini C
Thromb Haemost; 2022 May; 122(5):796-807. PubMed ID: 34530482
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Apixaban versus Dalteparin as a Treatment for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis.
Arce-Huamani MA; Barboza JJ; Martínez-Herrera JF; Torres-Roman JS; Maguiña JL
Medicina (Kaunas); 2023 Oct; 59(10):. PubMed ID: 37893585
[No Abstract] [Full Text] [Related]
12. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Rutjes AW; Porreca E; Candeloro M; Valeriani E; Di Nisio M
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD008500. PubMed ID: 33337539
[TBL] [Abstract][Full Text] [Related]
13. Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study.
Di Nisio M; van Es N; Carrier M; Wang TF; Garcia D; Segers A; Weitz J; Buller H; Raskob G
J Thromb Haemost; 2019 Nov; 17(11):1866-1874. PubMed ID: 31271705
[TBL] [Abstract][Full Text] [Related]
14. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.
Raskob GE; van Es N; Verhamme P; Carrier M; Di Nisio M; Garcia D; Grosso MA; Kakkar AK; Kovacs MJ; Mercuri MF; Meyer G; Segers A; Shi M; Wang TF; Yeo E; Zhang G; Zwicker JI; Weitz JI; Büller HR;
N Engl J Med; 2018 Feb; 378(7):615-624. PubMed ID: 29231094
[TBL] [Abstract][Full Text] [Related]
15. Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism: A Randomized Trial.
Planquette B; Bertoletti L; Charles-Nelson A; Laporte S; Grange C; Mahé I; Pernod G; Elias A; Couturaud F; Falvo N; Sevestre MA; Ray V; Burnod A; Brebion N; Roy PM; Timar-David M; Aquilanti S; Constans J; Bura-Rivière A; Brisot D; Chatellier G; Sanchez O; Meyer G; Girard P; Mismetti P;
Chest; 2022 Mar; 161(3):781-790. PubMed ID: 34627853
[TBL] [Abstract][Full Text] [Related]
16. Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study.
Ageno W; Vedovati MC; Cohen A; Huisman M; Bauersachs R; Gussoni G; Becattini C; Agnelli G
Thromb Haemost; 2021 May; 121(5):616-624. PubMed ID: 33202447
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for recurrence and major bleeding in patients with cancer-associated venous thromboembolism.
Vedovati MC; Giustozzi M; Munoz A; Bertoletti L; Cohen AT; Klok FA; Connors JM; Bauersachs R; Brenner B; Campanini M; Becattini C; Agnelli G
Eur J Intern Med; 2023 Jun; 112():29-36. PubMed ID: 36774305
[TBL] [Abstract][Full Text] [Related]
18. Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study.
Kraaijpoel N; Di Nisio M; Mulder FI; van Es N; Beyer-Westendorf J; Carrier M; Garcia D; Grosso M; Kakkar AK; Mercuri MF; Middeldorp S; Hernandez CR; Santamaria A; Schwocho L; Segers A; Verhamme P; Wang TF; Weitz JI; Zhang G; Zwicker JI; Büller HR; Raskob GE
Thromb Haemost; 2018 Aug; 118(8):1439-1449. PubMed ID: 30060256
[TBL] [Abstract][Full Text] [Related]
19. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.
Lee AYY; Kamphuisen PW; Meyer G; Bauersachs R; Janas MS; Jarner MF; Khorana AA;
JAMA; 2015 Aug; 314(7):677-686. PubMed ID: 26284719
[TBL] [Abstract][Full Text] [Related]
20. Apixaban versus Dalteparin for the Treatment of Acute Venous Thromboembolism in Patients with Cancer: The Caravaggio Study.
Agnelli G; Becattini C; Bauersachs R; Brenner B; Campanini M; Cohen A; Connors JM; Fontanella A; Gussoni G; Huisman MV; Lambert C; Meyer G; Muñoz A; Abreu de Sousa J; Torbicki A; Verso M; Vescovo G;
Thromb Haemost; 2018 Sep; 118(9):1668-1678. PubMed ID: 30103252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
